Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma

Bishoy A. Gayed, Jessica Gillen, Alana Christie, Samuel Peña-Llopis, Xian-Jin Xie, Jingsheng Yan, Jose A. Karam, Ganesh Raj, Arthur I Sagalowsky, Yair Lotan, Vitaly Margulis, James B Brugarolas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC).

METHODS: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables.

RESULTS: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤ 2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses.

CONCLUSION: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.

Original languageEnglish (US)
Pages (from-to)24
Number of pages1
JournalBMC Urology
Volume15
DOIs
StatePublished - Apr 3 2015

Fingerprint

Angiopoietin-2
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Nephrolithiasis
Pyruvate Kinase
Hematuria
Tumor Biomarkers
Nonparametric Statistics
Blood Vessels
Cysts
Neoplasms
Histology
Enzyme-Linked Immunosorbent Assay
Kidney

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. / Gayed, Bishoy A.; Gillen, Jessica; Christie, Alana; Peña-Llopis, Samuel; Xie, Xian-Jin; Yan, Jingsheng; Karam, Jose A.; Raj, Ganesh; Sagalowsky, Arthur I; Lotan, Yair; Margulis, Vitaly; Brugarolas, James B.

In: BMC Urology, Vol. 15, 03.04.2015, p. 24.

Research output: Contribution to journalArticle

@article{646c3b0cde3b463dbb64fe6ba8794489,
title = "Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma",
abstract = "BACKGROUND: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC).METHODS: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables.RESULTS: Median age was comparable between groups. 83/89 (93{\%}) of the cohort underwent surgical extirpation. 82{\%} of the tumors were organ confined (T ≤ 2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses.CONCLUSION: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.",
author = "Gayed, {Bishoy A.} and Jessica Gillen and Alana Christie and Samuel Pe{\~n}a-Llopis and Xian-Jin Xie and Jingsheng Yan and Karam, {Jose A.} and Ganesh Raj and Sagalowsky, {Arthur I} and Yair Lotan and Vitaly Margulis and Brugarolas, {James B}",
year = "2015",
month = "4",
day = "3",
doi = "10.1186/s12894-015-0019-4",
language = "English (US)",
volume = "15",
pages = "24",
journal = "BMC Urology",
issn = "1471-2490",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma

AU - Gayed, Bishoy A.

AU - Gillen, Jessica

AU - Christie, Alana

AU - Peña-Llopis, Samuel

AU - Xie, Xian-Jin

AU - Yan, Jingsheng

AU - Karam, Jose A.

AU - Raj, Ganesh

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

AU - Margulis, Vitaly

AU - Brugarolas, James B

PY - 2015/4/3

Y1 - 2015/4/3

N2 - BACKGROUND: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC).METHODS: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables.RESULTS: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤ 2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses.CONCLUSION: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.

AB - BACKGROUND: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC).METHODS: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables.RESULTS: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤ 2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses.CONCLUSION: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.

UR - http://www.scopus.com/inward/record.url?scp=85013740511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013740511&partnerID=8YFLogxK

U2 - 10.1186/s12894-015-0019-4

DO - 10.1186/s12894-015-0019-4

M3 - Article

VL - 15

SP - 24

JO - BMC Urology

JF - BMC Urology

SN - 1471-2490

ER -